Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Trastuzumab Her2'

Trastuzumab Her2 published presentations and documents on DocSlides.

6'DakoHercepTestTM for the Dako AutostainerCode K52071st editionFor im

6'DakoHercepTestTM for the Dako AutostainerCode K52071st editionFor im

  • katrgolden
  • 50 Slides

Contents PageIntended Use 4Summary and Explanation...

Module 9: HER2-Positive and

Module 9: HER2-Positive and

  • norah
  • 38 Slides

Triple-Negative Breast Cancer. Jamie Carroll, APRN...

Part B Medical Drugs Requiring Step

Part B Medical Drugs Requiring Step

  • udeline
  • 1 Slides

-TherapyDrug subject to Step TherapyTry these Opti...

Part B Medical Drugs Requiring StepTherapy

Part B Medical Drugs Requiring StepTherapy

  • natalie
  • 1 Slides

Drug subject to Step Therapy BRAND NAME GENERIC NA...

20 March 2014EMACHMP1518532014Committee for Medicinal Products for

20 March 2014EMACHMP1518532014Committee for Medicinal Products for

  • nicole
  • 3 Slides

Adoptedby CHMPfor release for consultation20 March...

Best practice for chemotherapy for treatment of breast cancer

Best practice for chemotherapy for treatment of breast cancer

  • ariel
  • 42 Slides

Andreas Makris. Mount Vernon Cancer Center. Royal ...

Dawid Sigorski, Ph.D .

Dawid Sigorski, Ph.D .

  • morgan
  • 65 Slides

Department. of . oncology. . UWM. Epidemiology. ...

Chemotherapeutic Treatment Options for Triple Negative Breast Cancer

Chemotherapeutic Treatment Options for Triple Negative Breast Cancer

  • iris
  • 30 Slides

Lauren Barney. April 17, 2013. Breast Cancer Subty...

Budget impact and cost-effectiveness of oncology

Budget impact and cost-effectiveness of oncology

  • roxanne
  • 14 Slides

biosimilars. Prof. dr. Steven Simoens. Health econ...

Cost Impact Of Biosimiliars in Oncology

Cost Impact Of Biosimiliars in Oncology

  • williams
  • 29 Slides

Mansoor A Khan, BS, MS, BCOP. Senior Clinical Phar...

DRUG NAMES AND MEDICATION ERRORS

DRUG NAMES AND MEDICATION ERRORS

  • freya
  • 13 Slides

1. DRUG NAMES. Chemical name. Development name use...

HER2 positive breast carcinoma in the pre and post adjuvant anti-HER-2 therapy era: a single academ

HER2 positive breast carcinoma in the pre and post adjuvant anti-HER-2 therapy era: a single academ

  • carny
  • 14 Slides

Heather M. Gage, MD, Avanti . Rangnekar. , Robert ...

Breast Cancer in Older Patients

Breast Cancer in Older Patients

  • ButterflyKisses
  • 51 Slides

Key Issues. Etienne GC . Brain. , MD . PhD. Instit...

Snyder D, Heidel RE, Panella T, Bell J, Orucevic

Snyder D, Heidel RE, Panella T, Bell J, Orucevic

  • Kingslayer
  • 19 Slides

A. University of Tennessee Medical Center – Knox...

Immunotherapy of Breast Cancer

Immunotherapy of Breast Cancer

  • WhereTheWildThingsAre
  • 27 Slides

World Congress on Breast Cancer . ...

Use specific response toward environment as a selective marker for therapy in breast cancer cells.

Use specific response toward environment as a selective marker for therapy in breast cancer cells.

  • BraveButterfly
  • 26 Slides

Hsiu. -Ni Kung. Anatomy and Cell Biology, Medical ...

Pathology of The Breast Lesions of female breast are much more common than lesions of male breast

Pathology of The Breast Lesions of female breast are much more common than lesions of male breast

  • PrincessPeach
  • 33 Slides

Most of these lesions are benign. Breast cancer i...

Nanotek & Expo 2014

Nanotek & Expo 2014

  • DaintyLittlePrincess
  • 16 Slides

Biodegradable . nanobrushes. for drug delivery. ...

ORIGINALARTICLEBREASTONCOLOGY

ORIGINALARTICLEBREASTONCOLOGY

  • emery
  • 8 Slides

SentinelLymphNodeBiopsyAfterNeoadjuvantChemotherap...

HER2 and Ki67Assessment of regional lymph nodesPhysical examination

HER2 and Ki67Assessment of regional lymph nodesPhysical examination

  • arya
  • 28 Slides

Luminal B-like (HER2-positive):!ER-positive!HER2-p...

Understanding Your Diagnosis29 Not all breast cancers are the same

Understanding Your Diagnosis29 Not all breast cancers are the same

  • adia
  • 7 Slides

ere are two separate ideas used when describi...

CoclusteringofErbB1andErbB2RevealedbyFRETSensitizedAcceptorBleachingg

CoclusteringofErbB1andErbB2RevealedbyFRETSensitizedAcceptorBleachingg

  • cora
  • 10 Slides

SubmittedDecember10,2009,andacceptedforpublication...

x0000x0000 xMCIxD 0 xMCIxD 0 xMCIxD 1

x0000x0000 xMCIxD 0 xMCIxD 0 xMCIxD 1

  • payton
  • 9 Slides

ENHERTUSignificantlyImproved Both ProgressionFree ...

Central Asian Journal of

Central Asian Journal of

  • cady
  • 10 Slides

15 Medical and Pharmaceutical Sciences Innovation ...

Antibody–Drug Conjugates in Development for Non-

Antibody–Drug Conjugates in Development for Non-

  • elizabeth
  • 49 Slides

s. mall Cell . Lung Cancer. , Gastric Cancer, and ...

Antibody–Drug Conjugates

Antibody–Drug Conjugates

  • wang
  • 55 Slides

in Development for . Breast Cancer. Sara A. Hurvit...

Antibody–Drug Conjugates: Practical Considerations and Applications in Clinical Use

Antibody–Drug Conjugates: Practical Considerations and Applications in Clinical Use

  • gelbero
  • 35 Slides

Sara A. Hurvitz, MD, FACP. Professor of Medicine. ...

Oncological perspective on Invasive lobular carcinoma

Oncological perspective on Invasive lobular carcinoma

  • elise
  • 20 Slides

Anne Sofie Brems-Eskildsen. Department of Oncology...

THBT neoadjuvant endocrine

THBT neoadjuvant endocrine

  • lucinda
  • 28 Slides

therapy. . is. to be . used. in post-. menopaus...

Adjuvant Therapy For Breast Cancer

Adjuvant Therapy For Breast Cancer

  • eddey
  • 46 Slides

. Breast Cancer | . Epidemiology- Australia. Austr...

Denise A. Yardley, MD Sarah Cannon Research Institute

Denise A. Yardley, MD Sarah Cannon Research Institute

  • lily
  • 29 Slides

Senior Investigator, . Breast Cancer Research. Ten...

SWAG guidelines Mark Beresford

SWAG guidelines Mark Beresford

  • natalie
  • 9 Slides

Oncotype. DX testing in network. Node negative â€...

Cutoff value for prominent biomarkers of breast cancer on overall survival using CART analysis

Cutoff value for prominent biomarkers of breast cancer on overall survival using CART analysis

  • eddey
  • 4 Slides

Pragya Kumari. 1. , . Atanu. Bhattacharjee. 2. , ...

Predictive marker update &

Predictive marker update &

  • ella
  • 35 Slides

multiparameter. molecular markers. September 25, ...

Risk of Heart Failure in Breast Cancer Patients After

Risk of Heart Failure in Breast Cancer Patients After

  • sophia2
  • 27 Slides

Anthracycline. and . Trastuzumab. Treatment: A R...

Module 8: ER-Positive Metastatic

Module 8: ER-Positive Metastatic

  • anastasia
  • 50 Slides

Breast Cancer . Elizabeth O’Reilly, MSN, MPH, AN...

Her2 + Breast Cancer Laura

Her2 + Breast Cancer Laura

  • ximena
  • 32 Slides

Bidstrup. Mrs B is a 49 . yo. woman who attended ...

Advanced Breast Cancer 31 year old female px severe pain right UL ‘burning’ pain

Advanced Breast Cancer 31 year old female px severe pain right UL ‘burning’ pain

  • margaret
  • 70 Slides

Background of lower back pain for 3/12 . No past ...

CA BREAST D r S ana

CA BREAST D r S ana

  • oconnor
  • 68 Slides

ishtiaq. . FCPS R3 general surgery unit one UKSO...

Changes in Breast Cancer Reports After Second Opinion

Changes in Breast Cancer Reports After Second Opinion

  • unita
  • 31 Slides

Dr. Vicente Marco. Department of Pathology. Hospit...

Copyright © 2024 DocSlides. All Rights Reserved